[Code of Federal Regulations]

[Title 42, Volume 1]

[Revised as of October 1, 2006]

From the U.S. Government Printing Office via GPO Access

[CITE: 42CFR24.4]



[Page 97]

 

                         TITLE 42--PUBLIC HEALTH

 

    CHAPTER I--PUBLIC HEALTH SERVICE, DEPARTMENT OF HEALTH AND HUMAN 

                                SERVICES

 

PART 24_SENIOR BIOMEDICAL RESEARCH SERVICE--Table of Contents

 

Sec.  24.4  Eligibility.



    To be eligible for appointment to the Service an individual must 

have a doctoral-level degree in biomedicine or a related field and must 

meet the qualification standards prescribed by the U.S. Office of 

Personnel Management for appointment to a position at GS-15 of the 

General Schedule. In addition, the individual must be outstanding in the 

field of biomedical research or clinical research evaluation. 

Appointment to the Service will be made only to individuals actively 

engaged in either biomedical research or clinical research evaluation.

    (a) Outstanding in the field of biomedical research means an 

individual who is actively engaged in peer-reviewed original biomedical 

research and whose work in this area is considered by his or her peers 

to be outstanding. In order to meet the eligibility criteria, an 

individual must have conducted original peer-reviewed biomedical 

research resulting in major accomplishments reflected by a steady and 

current record of highly cited publications in peer-reviewed journals of 

high stature. In addition, the individual should be the recipient of 

major prizes and awards (such as visiting professorships and named 

lectureships) in recognition of original contributions to research.

    (b) Outstanding in the field of clinical research evaluation means 

that an individual is actively engaged in clinical research evaluation 

and is considered by his or her peers to be outstanding. In order to 

meet the eligibility criteria, an individual, by force of his or her own 

technical expertise, must be in a position to shape the course of drug 

or device evaluation or exert a similar influence on the PHS handling of 

other agents that may affect the public health. The individual would 

normally have dealt with complex, precedent-setting evaluation issues 

that involved significant scientific controversy, had far reaching 

implications for clinical research or resulted in a widespread economic 

effect in the health-care delivery system. In addition, the individual 

should have been involved in the development of scientific or regulatory 

guidelines for clinical research and been the recipient of invitations 

to speak at or to chair major national or international meetings and 

symposia.